All feline diagnoses

Your cat was diagnosed with Primary Pulmonary Carcinoma. 90% are adenocarcinomas. 75% metastatic at diagnosis. Includes LUNG-DIGIT SYNDROME — a unique feline metastatic pattern where primary pulmonary carcinoma metastasises to the digits. The digit swelling may be the FIRST clinical sign noticed before the lung tumour is discovered. MST 67 days (Goldfinch & Argyle 2012). Diagnostic pathway: any cat with digit swelling → thoracic radiographs. Common in older cats. ENVIRONMENTAL RISK: Second-hand tobacco smoke exposure associated with increased risk (Bertone et al. 2002, PMID 12023141). Compare 5 treatment options for cats including Lung Lobectomy, Chemotherapy (Carboplatin or Mitoxantrone), Toceranib (Off-Label) — with survival times, costs, and what to expect during treatment.

🐈

Primary Pulmonary Carcinoma

feline

Epithelial

About This Cancer

Primary lung cancer in cats is most commonly an adenocarcinoma arising from the cells lining the airways or air sacs. A distinctive feature of feline lung cancer is its high rate of metastasis at the time of diagnosis — a high proportion of cats already have evidence of spread at the time of diagnosis. A particularly unusual metastatic pattern is the 'lung-digit syndrome,' in which the cancer spreads to the toes, causing swelling of one or more digits — sometimes the toe swelling is actually noticed before the lung tumour is discovered. Cats with solitary lung masses that have not yet spread can benefit from surgical lung lobectomy, but the high rate of advanced disease at diagnosis means that many cats are not surgical candidates. The disease mainly affects older cats, and symptoms include coughing, difficulty breathing, and weight loss.

Practical Staging for Feline Primary Pulmonary Carcinoma

No formal validated TNM system. Practical staging based on resectability and extent.

Stage Localised/ResectableSingle lobe, no LN or distant metastasis. Surgical candidate.
Stage MultifocalMultiple lobes affected or bilateral. Generally not surgical candidate.
Stage MetastaticDistant metastasis (including lung-digit syndrome). Palliative management.
Prognostic Factors(6)
Symptoms at presentationMost important prognostic factor. Asymptomatic MST 578 days vs symptomatic 4 days post-surgery. CAVEAT: The 4-day figure is post-surgical MST for cats symptomatic at lobectomy — reflects peri-operative mortality in severely diseased cats, not natural history of all symptomatic cats.(Maritato et al., 2014)
Histological differentiationGrade/differentiation affects prognosis
StageLocalized vs metastatic
Number of lung lobes affectedSingle lobe: better prognosis, surgically amenable. Multifocal: worse.(Hahn & McEntee, 1997)
Lymph node involvementTracheobronchial/hilar LN metastasis worsens prognosis significantly.
Histological type/differentiationAdenocarcinoma predominant (~90%). Differentiation may influence behaviour.(Hahn & McEntee, 1997)
Minimum Workup(7 steps)
1Thoracic radiographs (three views)
2CT chest (more sensitive for small nodules and extent assessment)
3Digit examination (lung-digit syndrome screening — check all digits for swelling)
4Abdominal ultrasound
5CBC, chemistry panel
6FNA or biopsy of lung mass (CT-guided)
7Regional lymph node assessment

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Lung Lobectomy
~19.3 mo
Chemotherapy (Carboplatin or Mitoxantrone)
See notes
Toceranib (Off-Label)
See notes
Palliation
~3.8 mo
Digit Amputation (Lung-Digit Syndrome)
~2.2 mo (1–4)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.